Chemical Name:N-[2-(1-Piperidinyl)-5-(trifluoromethyl)phenyl]-4-pyridinecarboxamide
Purity: ≥98% (HPLC)
Biological Activity
Technical Data
Solubility
Calculators
Datasheets
References
Biological Activity
Selective serine arginine protein kinase (SRPK) 1 inhibitor (Ki = 0.89 μM). Inhibits SRPK2 at higher concentrations. Does not significantly inhibit other SRPKs such as CLK1 and CLK4, or other classes of SR kinases. Down-regulates expression of VEGF165 but does not affect VEGF165b expression.
Compound Libraries
SRPIN340 is also offered as part of the
Tocriscreen Plus and Tocriscreen Kinase Inhibitor Toolbox II. Find out more about compound libraries available from Tocris.
Technical Data
M. Wt
349.35
Formula
C18H18F3N3O
Storage
Store at +4°C
Purity
≥98% (HPLC)
CAS Number
218156-96-8
PubChem ID
2797577
InChI Key
DWFGGOFPIISJIT-UHFFFAOYSA-N
Smiles
O=C(C3=CC=NC=C3)NC1=C(N2CCCCC2)C=CC(C(F)(F)F)=C1
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Solubility Data
Solvent
Max Conc. mg/mL
Max Conc. mM
Solubility
1eq. HCl
17.47
50
DMSO
34.94
100
ethanol
34.94
100
Preparing Stock Solutions
The following data is based on the product molecular weight 349.35. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass
1 mg
5 mg
10 mg
1 mM
2.86 mL
14.31 mL
28.62 mL
5 mM
0.57 mL
2.86 mL
5.72 mL
10 mM
0.29 mL
1.43 mL
2.86 mL
50 mM
0.06 mL
0.29 mL
0.57 mL
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
Product Datasheets
Certificate of Analysis / Product Datasheet
Safety Datasheet
Select another language:
View SDS
References
References are publications that support the products' biological activity.
Gammonset al (2013) SRPK1 inhibition modulates VEGF splicing to reduce pathological neovascularization in a rat model of retinopathy of prematurity. Invest.Ophthalmol.Vis.Sci. 54 5797 PMID: 23761094
Fukuharaet al (2006) Utilization of host SR protein kinases and RNA-splicing machinery during viral replication. Proc.Natl.Acad.Sci.USA 103 11329 PMID: 16840555
Olteanet al (2012) SRPK1 inhibition in vivo: modulation of VEGF splicing and potential treatment for multiple diseases. Biochem.Soc.Trans. 40 831 PMID: 22817743